Mayo Clinic and Bayesian Health have co-developed an AI solution to identify hospitalised patients who may benefit from palliative care earlier in their stay. The tool aims to improve care for patients with serious illness and reduce readmissions. A randomised clinical trial at Mayo Clinic showed the solution resulted in a 44% increase in timely palliative care referrals, a 25% reduction in 60-day readmissions and a 28% reduction in 90-day readmissions. The AI identifies unmet palliative care needs and provides clinicians with contextual information within their existing workflows. The solution runs on Bayesian Health's clinical intelligence platform, which continuously learns from clinician feedback and local patient populations. This marks Mayo Clinic's first AI collaboration spanning the entire care process in a complex hospital setting.

Bayesian Health has received FDA 510(k) clearance for its sepsis flagging device, marking the first continuous AI sepsis monitor to achieve regulatory approval. The clearance builds on the company's prior FDA Breakthrough Device Designation. The platform continuously monitors hospitalised patients and detects sepsis before clinical suspicion arises. A 2022 Nature Medicine study spanning 764,707 patient encounters across five hospitals showed patients were 18% less likely to die when clinicians acted on Bayesian's alerts, with detection occurring 5.7 hours earlier than traditional methods at 82% sensitivity. The clearance positions Bayesian favourably for approval under the Centers for Medicare and Medicaid Services' New Technology Add-on Payment programme starting October 2026, potentially providing hospitals with incremental reimbursement. The company has partnered with Cleveland Clinic and University of Rochester Medicine.